Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vosoritide for Short Stature in Turner Syndrome
NCT05849389Phase 2Recruiting
- Start
- Apr 2024
- Primary completion
- Sep 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vosoritide in Turner syndrome (TS). Primary endpoints: Incidence of treatment-emergent adverse events at 12 months, Change from baseline in annualized growth velocity at 12 months and 1 more. Started Apr 2024; status: recruiting.
02
Drugs
vosoritide
03
Conditions
Turner syndrome (TS)
Beyond the preview
Go deeper on NCT05849389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05849389.